International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR)
ISSN: 2582-7618 (Online), Volume-5 Issue-1, December 2024

Advancements in Antiviral Therapeutics: A Comprehensive Review of Hepatitis C Virus and Novel Flavone Leads

Juan Farhad Alrasho, Farhad Khalil Sofi, Nasser Thallaj

Abstract: ***This review explores the fundamental characteristics and implications of viruses, focusing on their classification, structure, and the specific case of Hepatitis C Virus (HCV). Viruses, nonliving biological entities reliant on host cells for replication, have been historically pivotal in understanding infectious diseases. The classification of viruses has evolved significantly, leading to a hierarchical system that categorizes them by order, family, genus, and species based on genomic characteristics and structural features. HCV, a member of the Flaviviridae family, presents a significant global health concern, affecting over 150 million people and causing approximately 500,000 deaths annually. The virus is characterized by its enveloped structure and single-stranded RNA genome, which encodes a polyprotein that is cleaved into functional proteins essential for viral replication and assembly. The epidemiology of HCV reveals regional prevalence variations, with higher rates observed in developing countries. Notably, the virus exhibits considerable genetic diversity, categorized into seven genotypes, each demonstrating different responses to treatment. The natural history of HCV infection is complex, often remaining asymptomatic for extended periods, which complicates diagnosis and treatment initiation. Chronic infections can lead to severe complications, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. Understanding the mechanisms of HCV entry, replication, and immune evasion is crucial for developing effective antiviral therapies and preventive measures. This review aims to provide a comprehensive overview of the current knowledge surrounding HCV, highlighting the need for ongoing research to better understand its biology and to improve therapeutic strategies against this pervasive virus.***

Keywords: Hepatitis C Virus; Antiviral Therapy; Flaviviridae; Viral Replication; Genotypes; Directly Acting Antivirals; Immune Evasion; Epidemiology.

I. INTRODUCTION

The Hepatitis C Virus (HCV) poses a significant global health challenge, affecting over 150 million individuals and leading to approximately 500,000 deaths annually. Understanding the intricate nature of HCV, including its classification, structure, and mechanisms of infection, is crucial for the development of effective antiviral therapies. This study aims to provide a comprehensive review of advancements in antiviral therapeutics targeting HCV, particularly focusing on novel flavone leads and the implications of these developments for future treatment strategies [1]. Historically, the classification of viruses has evolved significantly, revealing the complexity of their relationships and functions. HCV, classified within the Flaviviridae family, showcases considerable genetic diversity with seven distinct genotypes that exhibit varying responses to treatment. This diversity complicates therapeutic approaches and underscores the necessity for ongoing research to unravel the virus's biology [2]. The objectives of this review are threefold: first, to elucidate the structural and functional characteristics of HCV; second, to analyze the current landscape of antiviral therapies, particularly Directly Acting Antivirals (DAAs); and third, to highlight the potential of novel flavone compounds as promising therapeutic agents. By synthesizing existing literature and clinical findings, this review seeks to enhance understanding of HCV's pathogenic mechanisms and inform future directions in antiviral drug development. Ultimately, addressing the challenges posed by HCV is vital for improving patient outcomes and reducing the burden of this pervasive virus on global health [3].

A. Viruses

Viruses are biological entities that infect a wide range of organisms, including plants, animals, and bacteria, causing diseases by hijacking the host's metabolic machinery for replication. Major viral diseases include AIDS (which affected 35 million people globally and caused 1.5 million deaths in 2013),[1] Ebola, and smallpox (which has been eradicated). In the late 19th century, Martinus Beijerinck and Dmitri Ivanovsky independently discovered an infectious agent in plant extracts that could infect plants but not bacteria. Beijerinck coined the term "virus," which is still in use today. In 1935, Wendel Stanley crystallized the Tobacco Mosaic Virus, sparking debates about whether viruses are living organisms [2]. Viruses are now considered nonliving because they cannot self-replicate or store energy, but they do possess some characteristics of life, such as a genome and adaptability. Viruses rely on host cells for replication and energy. Outside host cells, viruses exist as virions—genetic material encased in a

Manuscript received on 21 November 2024 | Revised Manuscript received on 04 December 2024 | Manuscript Accepted on 15 December 2024 | Manuscript published on 30 December 2024.

*Correspondence Author(s)
Prof. Dr. Nasser Thallaj*, Department of Pharmaceutical Chemistry and Drug Quality Control, Faculty of Pharmacy, Al-Rachid Privet University, Damascus, Syria. Email ID: profthallaj@gmail.com, ORCID ID: 0000-0002-6279-768X
Juan Farhad Alrasho, Department of Pharmaceutical Chemistry and Drug Quality Control, Faculty of Pharmacy, Al-Rachid Privet University, Damascus, Syria.
Farhad Khalil Sofi, Department of Pharmaceutical Chemistry and Drug Quality Controlt, Faculty of Pharmacy, Al-Rachid Privet University, Damascus, Syria.

protein shell (capsid)—designed to protect the genome and facilitate entry into host cells Figure 1.



[Fig.1: Structure of the Tobacco Mosaic Virus, with the Capsid in Blue and The Genetic Material in Red]

The viral genome can be DNA or RNA, single-stranded (ss) or double-stranded (ds), and may be circular or linear [3]. For example, parvoviruses have a single linear DNA strand [4]. The capsid's primary role is to protect the genome, but it can also aid in host cell attachment. Capsids can have various shapes, such as helical, icosahedral, or rod-like structures, with helical and icosahedral being the most common. Viruses with only a capsid are non-enveloped, while many others have a lipid envelope surrounding the capsid [5].

B. Taxonomy

Virus classification, though initially simple, took years to formalize. In 1991, the International Committee on Taxonomy of Viruses (ICTV) defined a virus species as a group of viruses that share a replicating lineage and occupy a specific ecological niche [6]. Virus evolution follows the same principles as other organisms, but factors like high mutation rates, quasispecies, and genetic exchange complicate this process [7]. Virus classification serves as a tool to predict characteristics of newly discovered viruses based on their assigned category. Early virus classification began in the 1920s, grouping viruses by their effects on health (e.g., hepatitis viruses), but it wasn't until the 1950s, with the advent of the electron microscope, that classification based on viral particle size and shape emerged [8]. Today, viruses are classified hierarchically into orders, families, subfamilies, genera, and species, considering factors like nucleic acid type (DNA or RNA), strand orientation, reverse transcription, and gene coding. The ICTV recognizes seven major orders and over 2,500 virus species [9].

C. Classification Hierarchy:

- Order (-virales)
- Family (-viridae)
- Subfamily (-virinae)
- Genus (-virus)
- Species

II. ENVELOPED VIRUSES

A key feature for virus classification is the presence or absence of a viral envelope. In nonenveloped viruses, the protein capsid protects the genome, while in enveloped viruses, the lipid layer provides some protection. Both capsids and envelopes are essential for virus survival, as they help deliver the genetic material to new host cells [10]. These structures are typically composed of a few proteins but must fulfill several functions, such as packaging the genetic material, withstanding environmental conditions, and disassembling once inside the host cell [11]. Viruses can be classified based on the symmetry of the capsid into five categories:

- Helical nonenveloped
- Helical enveloped
- Icosahedral nonenveloped
- Icosahedral enveloped
- Complex virions

Helical viruses, like the tobacco mosaic virus (nonenveloped) and rabies virus (enveloped), have their genetic material organized around a central axis. Icosahedral viruses, like adenovirus (nonenveloped) and herpes simplex virus (enveloped), have spherical particles with symmetrical axes [12]. Some viruses, like smallpox, have more complex structures. Viruses with a lipid envelope include families such as Baculoviridae, Bunyaviridae, Coronaviridae, and others [13]. The envelope surrounds the nucleocapsid and typically consists of a lipid bilayer with embedded proteins that facilitate cell attachment and membrane fusion, crucial for virus entry [14]. Some viruses, like Iridovirus, have a lipid membrane inside the capsid rather than surrounding it Figure 2.



[Fig.2: Basic Structure of an Enveloped Virus]

Virion budding typically occurs when the nucleocapsid exits the host cell and moves into the extracellular space, with the viral envelope often derived from the host's cytoplasmic membrane [15]. However, the envelope can also come from the nuclear envelope, Golgi apparatus, or endoplasmic reticulum [16]. The lipid envelope is sensitive to environmental factors like solvents, extreme pH, high temperatures, and detergents [17]. Viruses embed their own proteins in the envelope, which are classified as integral or peripheral. Integral proteins have three domains: the extracellular domain (often glycosylated) for binding and fusion, the transmembrane domain anchoring the protein in the envelope, and the internal domain, which helps select viral proteins for the envelope [18]. Peripheral proteins, attached by hydrophobic and electrostatic interactions, help link the capsid and envelope during assembly [19].

While more fragile than capsids, the envelope offers advantages, such as protecting the virion from immune recognition by masking internal proteins and glycosylating external proteins to evade antibodies. Some viruses can even modify their lipid envelope to accommodate new proteins, a flexibility not possible with capsids [20]. Additionally, the envelope facilitates viral entry through improved membrane fusion. For naked viruses, entry occurs after irreversible attachment to the cell surface, followed by endocytosis [21]. Enveloped viruses first attach reversibly, then enter through fusion of the viral

envelope with the cell membrane or via endocytosis followed by fusion [22]. This fusion is catalyzed by viral glycoproteins, which may trigger the process either in a pH-independent manner (e.g., HIV) or in response to acidic conditions (e.g., influenza viruses). Hepatitis C Virus

Hepatitis C Virus (HCV) is one of the most widespread enveloped viruses, affecting over 150 million people globally and causing an estimated 500,000 deaths annually (including 2,600 deaths in France). This section will cover the history of its discovery, its biological characteristics, and the treatments used to combat the infection [23].

A. History of Hepatitis C Virus Infection

Viruses likely emerged with the earliest forms of life and have evolved over millennia. Hepatitis C Virus (HCV) is believed to have existed for hundreds of thousands of years. However, the earliest confirmed HCV-infected blood samples are only 50 years old. Following World War II, the rise in blood transfusions led to an increase in post-transfusion hepatitis cases. Initially, Hepatitis A Virus (HAV) and Hepatitis B Virus (HBV) were thought to be the culprits, but it was soon discovered that HAV was not transmitted through blood. In the 1960s and 1970s, tests for HBV (1963) and HAV (1973) were developed, but many cases tested negative for both. This led to the identification of "non-A, non-B hepatitis" (NANBH) [24]. Researchers soon realized that the cause was likely a small, enveloped virus. In 1989, the virus was identified by Bradley and Houghton, and in 1991, interferon became the first approved treatment. By 1992, a test to detect HCV in blood transfusions was introduced, preventing widespread infections, which had affected an estimated 300,000 people in the U.S. alone. Research on HCV has steadily increased, with over 1,500 publications by 2013[25].

B. Hepatitis C Virus Structure

Hepatitis C Virus (HCV) is a member of the Hepacivirus genus in the Flaviviridae family. It is an enveloped virus, measuring 55-65 nm in diameter, with a 30 nm capsid surrounding a single-stranded, positive-sense RNA genome [26]. The virus was once thought to be the only member of its genus, but other related viruses have since been discovered. The HCV particle consists of a spherical envelope surrounding an icosahedral capsid and the viral RNA [27]. Its 9.6 kb genome encodes a large polyprotein, which is cleaved by viral and host proteases into structural proteins (Core, E1, E2) and non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) Figure 3,4,5.



[Fig.3: Flaviviridae Phylogenetic Tree]



[Fig.4: Structure of Hepatitis C Virus]



[Fig.5: HCV Genome and Proteins]

The glycoproteins E1 and E2 are anchored in the viral lipid envelope. Both are heavily glycosylated and do not require activation through cleavage. They contain large N-terminal ectodomains and C-terminal transmembrane domains. E2 has a hypervariable region that mutates frequently, contributing to immune evasion. The small membrane protein p7 likely functions as an ion channel and is essential for producing infectious virions. Nonstructural proteins include NS2, which cleaves the polyprotein and is involved in apoptosis and lipid metabolism, and NS3, a helicase that forms a complex with NS4A to cleave the polyprotein and facilitate viral replication while disrupting the host immune response. NS4B aids in replication, assembly, and virion release. NS5A, associated with the endoplasmic reticulum, is crucial for replication, can inhibit replication through hyperphosphorylation, and suppresses the host's immune response by inhibiting PKR. Finally, NS5B is a polymerase essential for RNA replication. These proteins will be further discussed later [28].

III. HEPATITIS C VIRUS EPIDEMIOLOGY

Hepatitis C is globally endemic, but its prevalence varies by region. It is more common in some African and Asian countries, with prevalence rates as high as 11% in Bolivia, 13% in Cameroon, and 18% in Egypt. In contrast, Western Europe and North America have much lower rates, such as 0.1% in Germany and Ireland [29]. The high prevalence in Egypt is largely attributed to a past anti-schistosomal campaign that involved reusing syringes, contributing to widespread HCV transmission Figure 6.



[Fig.6: HCV Infection Epidemiology by Country]

Due to the long asymptomatic period of Hepatitis C, many individuals may remain

undiagnosed, making prevalence figures potentially inaccurate [30].

After the discovery of HCV, it became clear that isolates from different individuals and regions showed significant variability, leading to the identification of seven genotypes, which differ by about 35% in their sequence. These genotypes are further divided into 67 subtypes, with a 15% sequence variation. Certain genotypes are more common in specific regions: genotype 1 predominates in Western Europe and North America, while genotype 4 is more prevalent in the Middle East. Genotype 1 is associated with a higher risk of chronic infection and liver cancer, whereas genotype 3 is more commonly linked to steatosis. Additionally, treatment responses vary by genotype—genotype 1 is more resistant to treatment, with a clearance rate of 40-50%, while genotypes 2 and 3 have a higher clearance rate of 70-80%.

HCV also generates viral variants, or quasispecies, due to its high mutation rate (around 10^-3 per site) and the lack of proofreading in the NS5B polymerase. The virus has a rapid replication rate, with a half-life of 3-5 hours and a daily turnover of 10^12 virions [31]. This high replication rate and error frequency contribute to the large pool of viral variants within an infected individual Figure 7.

[Fig.7: HCV Genotype Distribution Worldwide]

A. Natural History of Hepatitis C Virus Infection

The natural history of a disease refers to its progression from exposure to resolution, without any medical intervention. Studying HCV's natural history is challenging due to its slow, asymptomatic progression, often taking decades before resolution or death. HCV is primarily transmitted through blood exposure, with high-risk groups including post-transfusion patients, healthcare workers, intravenous drug users, and hemodialysis patients. While sexual transmission and mother-to-child transmission occur, they are less common. Thanks to improved screening, HCV infection rates have decreased in developed countries [32].

B. Acute Hepatitis C

Acute Hepatitis C occurs in an estimated 30,000 cases annually. It is often asymptomatic, with symptoms like malaise, nausea, and jaundice appearing 3–12 weeks after exposure. Diagnosis can be challenging, as 30% of patients are negative for anti-HCV during acute infection. Spontaneous viral clearance happens in 20-25% of cases, particularly in younger, symptomatic patients. Factors like age, sex, and viral diversity influence the likelihood of spontaneous resolution [33].

C. Chronic Hepatitis C

Chronic infection is diagnosed when HCV RNA persists for six months after acute infection, affecting 75-80% of patients. Spontaneous clearance is rare, and risk factors for chronicity include older age, male gender, lack of symptoms during acute infection, HIV coinfection, and African American ethnicity. Chronic HCV can lead to extrahepatic conditions such as mixed cryoglobulinemia, glomerulonephritis, and porphyria. Liver fibrosis, caused by chronic inflammation, can progress to cirrhosis, occurring in 15% of chronic cases. Cirrhosis may eventually lead to hepatocellular carcinoma (HCC), particularly in cirrhotic patients [34].

HCV-related cirrhosis has a 2-4% annual mortality rate. Cirrhosis development typically takes 20 years, and HCC may develop 3 years after cirrhosis onset. Chronic hepatitis accounts for 25% of HCCs worldwide, a figure that is expected to rise due to the long-term progression of infection [35]. Identifying markers for self-limited infections and for early detection of cirrhosis and HCC remains a key area of research Figure 8.



[Fig.8: Scheme Depicting HCV Natural History]

D. HCV Reservoirs

The primary reservoir of Hepatitis C Virus (HCV) is hepatocytes in the liver, but it has also been detected in other cells such as peripheral blood mononuclear cells (PBMCs), dendritic cells, and T- and B-lymphocytes. The expression of microRNA-122 may facilitate HCV replication in non-hepatic cells. HCV can reinfect the liver after transplantation, suggesting that these alternative reservoirs may contribute to persistent infection. The virus replicates differently in these extrahepatic cells, with some affecting the immune system's function, particularly dendritic cells, which play a role in immune response. Infected non-hepatic cells may contribute to extrahepatic manifestations of HCV, as discussed in earlier sections [36].

E. HCV Infection Systems

The lack of efficient replication systems for HCV was a major challenge for research in the early years. Initial attempts using chronically infected patient cells yielded low replication levels. Advances came with the development of HCV replicons, which are versions of the virus genome capable of replication in cultured cells, helping to understand viral replication. The Huh-7.5 cell line, which supports high levels of HCV replication due to a mutation that inhibits the cellular antiviral response, became crucial in HCV studies. The development of

HCV pseudoparticles (HCVpp) and HCV cell culture systems (HCVcc) enabled the study of viral entry and replication in detail. However, a suitable animal model for HCV infection remained elusive for years [37].

F. Animal Models and Challenges

The chimpanzee was the primary animal model for HCV research, but its use was limited by ethical and cost concerns. Transgenic mice with human hepatocytes have recently shown promise in HCV studies, though they still face limitations in replicating the full spectrum of human HCV infection [38]. A better animal model is needed to bridge in vitro findings with clinical reality, improve preclinical testing of antiviral drugs, and advance HCV vaccine research. New models could also help assess drug toxicities and interactions Figure 9.



[Fig.9: Hepatitis C Virus Life Cycle]

G. HCV Entry

HCV's life cycle begins when the virus attaches to host cells, typically hepatocytes, in the bloodstream. Upon reaching the cell, the virus binds to specific receptors on the cell surface, enabling its entry Figure 10.



[Fig.10: HCV Entry in the Cell]

HCV entry begins with a low-affinity attachment to the host cell via receptors such as LDLR, glycosaminoglycans (GAGs), and apoE, which is present in the viral envelope. This initial binding is electrostatic and not highly specific, aiding in attachment. LDLR plays a key role in HCV interactions with hepatocytes, and although some HCV particles may not be internalized by the typical pathway, LDLR contributes to viral replication by supplying lipids. Following attachment, the viral glycoprotein E2 binds to SR-BI, which facilitates virus entry by interacting with lipoproteins and triggering a conformational change in the viral envelope. This change exposes a region of E2 that binds CD81, a tetraspanin protein essential for HCV entry. CD81 interaction with the virus primes it for low-pH activation, and its signaling helps localize the virus at tight junctions [39]. CLDN-1, a protein found at tight junctions, is crucial for HCV internalization, working with CD81 to facilitate entry. CLDN-1 interacts with CD81 and may bind directly to the viral envelope, triggering endocytosis via clathrin Figure 11.



[Fig.11: HCV Entry Through Tight Junctions]

HCV entry into host cells requires multiple factors. Occludin (OCLN), a 60 kDa tight junction protein, plays a role in the post-attachment step of HCV entry, though its exact function remains unclear. Unlike CLDN-1, OCLN does not interact directly with HCV glycoproteins but may participate in the fusion process. After endocytosis, the HCV complex is transported to endosomal compartments, where SR-BI and NPC1L1 further modify the virus and its lipoproteins. E2 glycoprotein interaction with CD81 is thought to prime HCV for fusion by responding to low pH, triggering exposure of the fusion peptide. E1 glycoprotein may also contribute to viral fusion by exposing its fusion peptide or inducing a conformational change in E2. Once fusion occurs, the viral genome is released into the cytosol for translation and replication. Recently, transferrin receptor 1 (TfR1) was identified as another factor in HCV entry, likely functioning after CD81 binding during endocytosis. Additionally, the buoyant density of the viral particle affects infectivity, with lower density fractions showing higher fusogenicity. Structural insights into the E2 glycoprotein will aid in understanding the interactions and conformational changes involved in HCV entry [40].

Once the viral genome is in the cytoplasm, it is translated via an Internal Ribosome Entry Site (IRES), bypassing the need for a 5' cap structure. The IRES recruits ribosomal subunits, forming an 80S complex for polyprotein translation, which includes structural proteins (C, E1, E2), ion channel protein p7, and nonstructural proteins (NS2, NS3A, NS4A, NS4B, NS5A, and NS5B). These proteins are processed co- and post-translationally by host enzymes, with cleavages occurring at specific sites to form mature proteins. NS2/3 protease and NS3 also play

roles in processing, and NS3 serves as a helicase. NS4A is essential for activating NS3 protease, and NS3-4A suppresses host antiviral responses by cleaving the immune protein TRIF. NS4B induces the formation of the membranous web, a structure involved in viral replication, while NS5A's phosphorylation status regulates replication [41]. NS5B, the RNA-dependent RNA polymerase, synthesizes negative-strand RNA and, in conjunction with NS5A, produces new viral genomes.

HCV replication occurs on vesicular membranes of the endoplasmic reticulum, where nonstructural proteins form a replication complex, likely assisted by cellular cofactors such as PTB, glyceraldehyde-3-phosphate dehydrogenase, and miRNAs.

Viral assembly involves the interaction of structural proteins (E1, E2, and C) with the viral RNA at the endoplasmic reticulum. Core protein relocation to lipid droplets, directed by DGAT1, likely plays a role in the assembly process. The p7-NS2 complex may aid in the assembly by interacting with E1-E2 and NS3-4A complexes, leading to RNA encapsidation and capsid envelopment at the endoplasmic reticulum membrane. The virus matures and acquires a lower density when it interacts with the host's VLDL machinery. As the virus progresses through the secretory pathway, glycoproteins E1 and E2 undergo post-translational modifications, and p7 helps protect the virion from low pH during cell egress. Once matured, the virus can be secreted or transmitted directly between cells, the latter of which may facilitate faster spread and immune evasion [42].

Therapeutic advancements in HCV treatment have accelerated in recent years, with the development of Directly Acting Antivirals (DAAs) targeting various stages of the viral lifecycle. Early treatments like interferon (IFN-α) had limited efficacy, with a low sustained virologic response (SVR). The addition of ribavirin improved outcomes, and the development of pegylated IFN (PEG-IFN) extended its half-life, increasing SVR. However, IFN-based therapies were associated with significant side effects. Interferons induce an antiviral state by stimulating host immune responses, but their broad effects also contribute to side effects. Type I interferons (α, β, ω) activate the JAK-STAT pathway, while Type III interferons (λ) bind to receptors on epithelial cells, potentially reducing side effects. Ribavirin, initially used as monotherapy, showed minimal effect against HCV but became part of a successful combination therapy with IFN. This combination remained the standard of care for chronic HCV until the recent introduction of DAAs, revolutionizing treatment Figure 12.



Figure 12. Chemical Structure of Ribavirin and Viramidine

Despite extensive use in anti-HCV therapy, the exact mechanism of action of ribavirin (RBV) remains unclear. Several proposed mechanisms include: (1) inducing viral mutagenesis through nucleotide transitions, (2) directly inhibiting HCV RNA-dependent RNA polymerase (RdRp) to disrupt replication, (3) reducing GTP synthesis, thereby limiting viral replication, (4) modulating the host immune response by suppressing Th2 and promoting Th1 responses, and (5) enhancing interferon signaling by modulating related genes. The unresolved mechanism complicates efforts to improve RBV's antiviral efficacy [43].

A significant limitation of RBV is its side effects, which often lead to therapy discontinuation. These include anemia, fatigue, pruritus, sinusitis, and abdominal pain. Increasing the RBV dose to enhance sustained virologic response (SVR) has been linked to more severe side effects. To address this, a prodrug, Viramidine, was developed, offering fewer side effects but also reduced antiviral activity [44].

Improving the IFN-RBV combination therapy remains challenging without a deeper understanding of RBV's mode of action. Additionally, many patients either cannot tolerate or do not respond well to dual therapy due to its adverse effects. Although the development of new anti-HCV drugs has accelerated, RBV will likely continue to be used in combination with these newer therapies [45].

Directly Acting Antivirals (DAAs)

Recent years have seen the approval of several new drugs for hepatitis C treatment, marking a significant advancement in anti-HCV therapy. By 2011, over 50 companies were involved in HCV research, and by 2013, clinical trials for more than 12 new compounds were underway. These drugs target and inhibit specific steps in the viral life cycle, leading to improved sustained virologic response (SVR) rates across all genotypes. Studies suggest that interferon-based therapies may soon be replaced by all-oral DAA-based treatments due to their higher efficacy and tolerability. Remarkably, it took 22 years from the discovery of HCV to the introduction of the first DAAs, likely due to challenges in in vitro testing and the initially low perceived market potential [46].

NS3/4A Protease Inhibitors

Telaprevir, Boceprevir, and Simeprevir are three NS3/4A inhibitors already approved for use. Telaprevir and Boceprevir were FDA-approved in 2011, while Simeprevir, a second-generation inhibitor, was approved in 2013. Additionally, eleven other NS3/4A inhibitors are still in clinical development. The structures of thirteen such compounds are shown in Figure 13.



[Fig.13: NS3/4A Protein Inhibitors Approved or Under Development]

Telaprevir, developed by Vertex, was approved by the FDA in 2011. It binds to the NS3/4A protease in a two-step process, dissociating the NS3/4A complex and inhibiting the cleavage of the polyprotein into its functional components (NS4A, NS4B, NS5A, and NS5B), which is essential for HCV replication. Telaprevir is selective and does not affect other proteases. When used in combination with interferon (IFN) and ribavirin (RBV), it improves sustained virologic response (SVR) rates to 75% in genotype 1 patients and reduces treatment duration. However, Telaprevir can cause side effects such as rash, anemia, and gastrointestinal issues. Boceprevir, also approved in 2011, has a similar mechanism of action and similarly improves SVR rates to 75% in genotype 1 patients [47].

A major limitation of these first-generation NS3/4A inhibitors is their low genetic barrier to resistance, with resistant mutations emerging quickly. Therefore, both Telaprevir and Boceprevir are used in triple therapy with IFN and RBV. Additionally, these inhibitors are prone to significant drug-drug interactions [48].

Simeprevir, a second-generation NS3/4A inhibitor approved by the FDA in 2013, is dosed once daily and does not induce anemia. It improves SVR rates up to 85%, though resistance can develop in patients with poor response, reducing SVR [49].

Despite the improvements in SVR rates with NS3/4A inhibitors, response rates remain suboptimal, and side effects can lead to treatment discontinuation for some patients [50].

NS5A Protein Inhibitors NS5A is a critical protein in the replication and assembly of the HCV virus, making it an ideal target for antiviral therapy. While the exact mechanism of action is unclear, it is believed that NS5A inhibitors may interact with the N-terminus of the protein, potentially inhibiting hyperphosphorylation, which is crucial for its function. These inhibitors exhibit extremely low EC50 values in the nanomolar and even picomolar ranges but also have a low barrier to resistance. NS5A-resistant variants are often present in the quasispecies pool prior to treatment, and can rapidly dominate after DAA administration. Currently, no NS5A inhibitors have been approved for use [51].

Among the NS5A inhibitors in development, Daclatasvir has an EC50 of 50 pM against genotype 1a, and Ledipasvir, when combined with Sofosbuvir, achieves 100% SVR rates. It is hypothesized that NS5A forms a dimer, which may explain the high potency of symmetric compounds targeting it [52]. Given their potency, specificity, and low EC50, NS5A inhibitors are likely to be incorporated into future HCV therapies, either in combination with IFN and RBV or as part of all-oral regimens. Second-generation NS5A inhibitors are also being developed, showing improved resistance profiles while maintaining similar efficacy Figure 14.



[Fig.14: NS5A Inhibitors Under Development]

IV. NS5B POLYMERASE INHIBITORS

NS5B polymerase inhibitors are classified into two categories: nucleoside and non-nucleoside inhibitors. Nucleoside inhibitors are analogs of natural NS5B RdRp substrates and, once incorporated into the growing RNA chain, cause chain termination by binding to the active site of NS5B. These inhibitors require phosphorylation to their triphosphate form for activation. Due to the high conservation of NS5B across various HCV genotypes and subtypes, nucleoside inhibitors are generally effective against all genotypes and possess high genetic resistance barriers. Figure 15 illustrates several nucleoside inhibitors [53].



[Fig.15: NS5B Nucleoside Inhibitors Approved or Under Development]

Non-nucleoside inhibitors bind to allosteric sites on the NS5B enzyme, inducing conformational changes that inhibit its polymerase activity. Unlike nucleoside inhibitors, their effectiveness is genotype-dependent, and they have a lower genetic resistance barrier. However, because they target distinct allosteric sites, combination therapy with multiple non-nucleoside inhibitors may be a viable approach. Figure 16 shows various non-nucleoside inhibitors [54].



[Fig.16: Non-Nucleoside NS5B Inhibitors Approved or Under Development]

Sofosbuvir, a well-known NS5B nucleoside polymerase inhibitor, was FDA-approved in 2013 for chronic hepatitis C treatment. It is used in combination with PEG-IFN and RBV for genotypes 1 and 4, and with RBV alone for genotypes 2 and 3. IFN-free therapy with Sofosbuvir has a low discontinuation rate and fewer side effects compared to PEG-IFN-based treatment. SVR rates are high for most genotypes, except genotype 3, which requires longer treatment. In combination with Ledipasvir (an NS5A inhibitor), Sofosbuvir achieves up to 100% SVR in genotype 1 patients after 12 weeks. NS5B inhibitors are a promising class for future all-oral, IFN-free therapies [55].

A. Other Antiviral Agents

In addition to NS3/4A, NS5A, and NS5B inhibitors, several other antiviral drugs are being developed, including those targeting host-cell proteins. For instance, Cyclophilin A inhibitors like Alisporivir and miRNA-122 inhibitors such as Miravirsen are under investigation. A promising new class of drugs are entry inhibitors, which block the virus during its initial stages of infection. These inhibitors target host-cell factors involved in viral entry, potentially preventing the virus from introducing its genetic material into the cell. This approach may be particularly beneficial for patients receiving liver transplants, where current therapies show limited efficacy [56]. Moreover, mutations affecting viral entry occur less frequently than mutations in viral proteins, making entry inhibitors an attractive option. Additionally, entry inhibitors may be pangenotypic, as different HCV genotypes use similar mechanisms for cell entry. However, the development of these inhibitors has been hindered by the lack of efficient animal models and cell culture systems. The advent of HCV pseudoparticles (HCVpp) and cell culture systems (HCVcc) in 2003 and 2005 facilitated the screening of entry inhibitors. Currently, various entry inhibitors, such as CD81-targeting antibodies and small molecules like Ezetimibe, are being explored. ITX5061, a small molecule targeting SR-BI, is already in phase 1b trials. In the future, entry inhibitors may be combined with DAAs to prevent liver graft reinfection or to treat relapsed patients Figure 17.



[Fig.17: Other Antiviral Agents Under Study]

B. Future Therapies

Anti-HCV research is expected to progress rapidly, with the goal of developing new treatments that address the limitations of current DAAs, such as improving genetic resistance barriers, reducing side effects, and enhancing efficacy. Future therapies

aim to provide once-daily, all-oral, IFN-free regimens with broad antiviral activity across all genotypes and variants. This could be achieved by combining drugs that target different stages of the viral lifecycle. Additionally, the role of RBV may diminish over time, eliminating its associated side effects. Future therapies may combine two DAAs with host-targeting agents, such as entry inhibitors [57].

Currently, no vaccine for HCV exists, primarily due to the lack of suitable animal models and the virus's high variability across genotypes and subtypes. Neutralizing antibodies targeting the viral E2 glycoprotein have shown some promise but are limited by the virus's ability to evade them through variability. An alternative approach is to target conserved nonstructural proteins to elicit a broad T-cell response, which, combined with new animal models and cell culture systems, could expedite vaccine development [58].

Although DAAs have revolutionized HCV treatment, access to these therapies remains limited, especially in low-income countries, which account for 80% of global HCV infections. The high cost of new treatments, such as Sofosbuvir ($1,000 per pill) and Simeprevir ($66,000 for a 12-week course), exacerbates this issue. There is still a significant need for affordable drugs that target various steps of the HCV lifecycle to ensure global access to treatment.

C. Flavonoids

Flavonoids are naturally occurring polyphenolic compounds found throughout the plant kingdom, particularly in fruits, seeds, flowers, and vegetables, making them an essential part of the human diet. These compounds have been extensively studied for their wide range of biological activities, including antiviral, antibacterial, and antioxidant properties.

The study of flavonoids began in 1664 with Boyle's exploration of the effects of acids and bases on flavonoid pigments. Their chemical composition was first described in the 19th century, and since then, significant research has been conducted. In recent decades, the growing recognition of their biological effects has further fueled interest in their potential applications.

D. Structure of Flavonoids

Flavonoids basic structure is characterized by the presence of a benzo-γ-pyrone motif, a C6-C3-C6 carbon skeleton. The three different rings are referred to as A, B and C respectively and atom are numbered as depicted in Figure 18.



[Fig.18: Basic Structure of Flavonoids]

Flavonoids, despite sharing a common basic structure, encompass a vast array of different structural forms. They represent the largest group within the polyphenol family, with over 6,000 identified compounds. The main subclasses of flavonoids include flavans, flavanols (catechins), flavanones, flavanonols, flavones, flavonols, anthocyanidins, and chalcones (Figure 19). Neoflavonoids and isoflavonoids are also considered flavonoids, though they differ by a shift in the phenyl moiety to the 4- and 3-position, respectively. These subclasses also exhibit variations in hydroxylation and saturation. Another distinct group, aurones, differ in structure by having a five-membered C ring rather than the typical six-membered ring. The structural diversity of flavonoids is further enhanced by modifications such as hydroxylation, methoxylation, glycosylation, and glucuronidation, contributing to their wide range of biological properties.



[Fig.19: Structure of Different Flavonoids]

E. Occurrence and Role of Flavonoids

Flavonoids are widespread in plants, particularly in photosynthesizing species, and are generally absent in algae. Different plant families produce specific flavonoids based on their functional roles. These secondary metabolites are synthesized via the flavonoid pathway in the cytosol, starting from phenylalanine and malonyl-CoA. Once produced, flavonoids are transported to various cellular compartments such as the leaves, mesophyll cell nuclei, chloroplasts, and vacuoles, where they perform their functions.

Flavonoids are believed to have evolved early in Earth's history to protect plants from UV-B radiation as they transitioned from water to land. UV-B radiation can generate reactive oxygen species (ROS), damaging DNA, proteins, and membranes. Chalcones, flavonols, and flavones are found in mosses, the first land plants, but are absent in algae. Even today, flavonoids primarily protect plants from UV radiation by modulating the antioxidant system to prevent mutagenesis. Mutant plants lacking flavonoids show increased sensitivity to UV light.

Flavonoids also play significant roles in plant signaling. They can function as allelochemicals, affecting interactions between plants by inhibiting the growth of neighboring competitors. Additionally, flavonoids serve as signaling molecules for microbes and bacteria; for instance, quercetin, a common flavone, has been shown to inhibit microbial growth.



[Fig.20: Structures of Flavonoids Quercetin, Peonidin and Petunidin]

Flavonoids serve several key functions in plants, including pigmentation in fruits and flowers. Their

primary role in pigmentation is to attract animals for pollination and seed dispersal. Anthocyanins, which give rise to colors ranging from blue to red, are the main pigments responsible. For instance, petunidin is found in *Vicia villosa* flowers, and peonidin is present in grapes. Yellow flowers and fruits typically contain chalcones and aurones. The color variation of these pigments is influenced by the presence and position of hydroxyl groups Figure 20.

Flavonoids also regulate plant growth, potentially acting as cofactors in the regulation and transport of the growth hormone auxin. Additionally, they are believed to play a crucial role in pollen fertility.

Another important function of flavonoids is in plant defense, where many compounds exhibit antifungal and insecticidal properties. These defensive flavonoids may be synthesized in response to pathogen attacks or preformed during normal plant development.

F. Flavonoids and Human Diet

Flavonoids are commonly found in a wide range of plants, making them an integral part of the human and animal diet. They are present in various foods and beverages, including red wine, tea, fruits, cereals, nuts, and vegetables, with their levels and types varying depending on the source. For instance, green tea contains unique flavonoids such as GalloCatechin (GC), EpiGalloCatechin (EGC), and EpiGalloCatechin Gallate (EGCG). Additionally, up to 35% of dry tea matter consists of flavonoids and other phenolic compounds. Black chocolate is another source, containing 610 mg/kg of catechins. Flavonoids, along with other polyphenols, contribute to the taste of many foods and beverages Figure 21.



[Fig.21: Structures of Catechin Derivatives Present in Green Tea]

Accurate data on flavonoid dietary intake is currently unavailable, though several estimates have been proposed. Kühnau estimated that the average daily intake of flavonoids in the United States is about 1 g, but this figure may be overestimated due to limitations in analytical methods. More recent estimates suggest a daily intake of approximately 25 mg for flavones, flavanones, and flavonols. The Phenol-Explorer database (http://phenolexplorer.eu) provides detailed information on polyphenol content in foods, currently listing 518 polyphenols. Once consumed, flavonoids are likely digested and absorbed in the gut, then metabolized in the liver. Glycoside-bound flavonoids are typically metabolized after bacterial glycosidases hydrolyze them in the upper intestine Figure 22.



[Fig.22: Summary of the Formation of Gastrointestinal Tract and Hepatic Metabolites and Conjugates of Flavonoids in Humans]

G. Biological Activities of Flavonoids

Flavonoids are known to provide various health benefits through pleiotropic actions. Herbal medicines, used for centuries, often contain flavonoids, which contribute to their therapeutic effects. For example, *Radix Scutellariae*, commonly used in traditional Chinese medicine for treating inflammatory conditions and diarrhea, contains flavonoids such as baicalein, baicalin, and wogonin. Similarly, flavonoids in plants used in traditional Mexican medicine have shown therapeutic potential against diarrhea. Recently, interest in flavonoids has increased due to their broad range of therapeutic effects Figure 23.



[Fig.23: Structures of Baicalein, Baicalin and Wogonin]

Flavonoids are primarily studied for their antioxidant activity, although they are not the most potent antioxidants among polyphenols. Reactive oxygen species (ROS) generated during normal metabolism are thought to contribute to cellular aging, mutagenesis, and carcinogenesis by causing DNA damage or oxidizing LDL. Flavonoids act as effective radical scavengers due to their conjugated rings and hydroxyl groups, which enable them to neutralize free radicals and active species. Their ability to chelate prooxidant metal ions like Cu(I) and Fe(II) also contributes to their antioxidant effects. Additionally, flavonoids, including quercetin, genistein, daidzein, and EGCG, have demonstrated anticarcinogenic properties. Although the exact mechanisms are not fully understood, flavonoids may influence tumor initiation, promotion, and progression. For instance, citrus flavonoids such as naringenin, eriodictyol, and hesperetin show antiproliferative effects on cancer cells Figure24.



[Fig.24: Structures of Naringenin, Eriodyctiol, Hesperetin, Quercetin, Genistein and Daidzein]

Flavonoids offer protective effects against heart disease by preventing LDL oxidation and platelet aggregation. It is suggested that a higher intake of flavonoid-rich foods and beverages may lower the risk of heart disease, as evidenced by the lower heart disease rates in countries with higher flavonoid consumption. Additionally, flavonoids demonstrate hepatoprotective properties, such as those found in *Laggera alata*, which protect against carbon tetrachloride-induced liver damage. Many flavonoids, including apigenin and galangin, exhibit antibacterial activity, likely due to their role in plant defense. Flavonoids have also been shown to possess anti-inflammatory effects by inhibiting enzymes involved in the inflammatory process. Furthermore, certain flavonoids, such as baicalin and robinetin, have antiviral properties, inhibiting infections like HIV and Dengue Virus (DENV). Luteolin, when combined with kaempferol, enhances the antiviral activity against Herpes Simplex Virus Figure 25.



[Fig.25: Structures of Apigenin, Galangin and Robinetin]

Flavonoids have also been shown to exhibit antidiabetic, antitrypanosomal, antipsoriasis, and antineurodegenerative properties.

V. CONCLUSION

This review highlights the critical aspects of Hepatitis C Virus (HCV), from its complex biology and epidemiology to the ongoing advancements in antiviral therapies. HCV remains a significant global health challenge, affecting millions and leading to serious complications such as cirrhosis and hepatocellular carcinoma. The intricate nature of the virus, characterized by its genetic diversity and ability to evade host immune responses, complicates diagnosis and treatment.

Recent developments in directly acting antivirals (DAAs) have transformed HCV management, offering highly effective treatment options that significantly improve sustained virologic response rates across various genotypes. However, challenges remain, including the need for improved resistance profiles and the management of side effects associated with existing therapies.

Future research should focus on enhancing our understanding of HCV pathogenesis, exploring novel therapeutic strategies, and ultimately, developing a robust vaccine. Continued efforts in this field are essential to mitigate the burden of HCV and improve patient outcomes worldwide. As our knowledge evolves, so too must our strategies to combat this pervasive virus, ensuring that we are equipped to confront the challenges it presents.

DECLARATION STATEMENT

After aggregating input from all authors, I must verify the accuracy of the following information as the article's author.

- **Conflicts of Interest/ Competing Interests:** Based on my understanding, this article has no conflicts of interest.
- **Funding Support:** This article has not been sponsored or funded by any organization or agency. The independence of this research is a crucial factor in affirming its impartiality, as it has been conducted without any external sway.
- **Ethical Approval and Consent to Participate:** The data provided in this article is exempt from the requirement for ethical approval or participant consent.
- **Data Access Statement and Material Availability:** The adequate resources of this article are publicly accessible.
- **Authors Contributions:** The authorship of this article is contributed equally to all participating individuals.

REFERENCES

1. Machkour A, Thallaj NK, Benhamou L, Lachkar M, Mandon D.Chemistry. 2006 Aug 25;12(25):6660-8.P 6660-6661-6662-6663. DOI: https://doi.org/10.1002/chem.200600276.
2. Thallaj, N., Machkour, A., Mandon, D., Welter, R., New. J. Chem., 2005, 29, 1555 – 1558. DOI: https://doi.org/10.1039/B512108F
3. Thallaj NK, Rotthaus O, Benhamou L, Humbert N, Elhabiri M, Lachkar M, Welter R, Albrecht-Gary AM, Mandon D. Chemistry. 2008;14(22):6742-53.P6745-6746-6747. DOI: https://doi.org/10.1002/chem.200701967
4. Wane A, Thallaj NK, Mandon D. Chemistry. 2009 Oct 12;15(40):10593-602. P10594-10595-10595. DOI: https://doi.org/10.1002/chem.200901350
5. Thallaj NK, Orain PY, Thibon A, Sandroni M, Welter R, Mandon D. Inorg Chem. 2014 Aug 4;53(15):7824-36. P7826-7827-7828. DOI: https://doi.org/10.1021/ic500096h
6. N. K. Thallaj, J. Przybilla, R. Welter and D. Mandon, J. Am. Chem. Soc. 2008, 130, 2414-2415. DOI: https://doi.org/10.1021/ja710560g
7. N. K. Thallaj, D. Mandon and K. A. White, Eur. J. of Inorg. Chem., 2007, 44–47. DOI: https://doi.org/10.1002/ejic.200600789.
8. Thallaj, N.; International journal of applied chemistry and biological sciences 2021, 2 (4), 65-77. https://identifier.visnav.in/1.0001/ijacbs-21f-07003/
9. Thallaj, N. (2023). Review of a Few Selected Examples of Intermolecular Dioxygenases Involving Molecular Oxygen and Non-Heme Iron Proteins. *Int. J. Adv. Parmacutical Sci. Res.(IJAPSR)*, *3*, 1-18. DOI: https://doi.org/10.54105/ijapsr.C4011.023223
10. L. Labban, M. Kudsi, Z. Malek, N. Thallaj; Advances in Medical, Dental and Health Sciences, 2020,3, 3,45-48. DOI: https://doi.org/10.5530/amdhs.2020.3.11
11. L. Labban, N. Thallaj, M. Al Masri; Journal of Advanced Research in Food Science and Nutrition, 2020,3,1,34-41. DOI: https://doi.org/10.11648/j.wjfst.20190304.11.
12. L. labban; N. thallaj; A. labban; archives of medicine, 2020, 12, 2:8, 1-5. DOI: https://doi.org/10.36648/1989-5216.12.2.309
13. L. Labban, N. Thallaj, Z. Malek; Journal of Medical Research and Health Sciences, 2019, 2, 11, 784-787. DOI: https://doi.org/10.15520/jmrhs.v2i11.128
14. Malek, Z.S.; Sage D.; Pevet, P.; Raison, S.; Endocrinology 2007, 148 (11), 5165-5173. DOI: https://doi.org/10.1210/en.2007-0526

15. Malek, Z.S.; Dardente, H.; Pevet, P.; Raison, S.; European Journal of Neuroscience 2005, 22 (4), 895-901. DOI: https://doi.org/10.1111/j.1460-9568.2005.04264.x
16. Malek, Z.S.; Pevet, P.; Raison, S.; Neuroscience 2004, 125 (3), 749-758. DOI: https://doi.org/10.1016/j.neuroscience.2004.01.031
17. Malek, Z.S.; Labban, L.; The International Journal of Neuroscience, 2020, 1-7. DOI: https://doi.org/10.1080/00207454.2020.1782903
18. ZS Malek, LM Labban; Journal of current research in physiology and pharmacology, 2020, 4, (1),1-5. DOI: https://doi.org/10.31878/ijcrpp.2020.41.01.
19. L.M. Labban, M. M. Alshishkli, A. Alkhalaf, Z. Malek; J. Adv. Res. Dent. Oral Health, 2017, 2(3&4), 1-4. DOI: https://doi.org/10.24321/2456.141X.201702.
20. L Labban, ZS Malek, Open Access Library Journal, 2018, 5 (07), 1-11. DOI: https://doi.org/10.4236/oalib.1104654.
21. Y. alhomush, Z. malek, A. Abboud, N.Thallaj, Research Journal of Pharmacy and Technology, 2022, 15, 10. DOI: https://doi.org/10.52711/0974-360X.2022.00794.
22. A.Abbood, Z.Malek, N.Thallaj. 2022 15, 11, 4935-4939. Research Journal of Pharmacy and Technology. DOI: https://doi.org/10.52711/0974-360X.2022.00829.
23. Thallaj, N; agha, M. I ,H;, nattouf; A.H; katib, CH; karaali, A; Moustapha, A; Labban L;open access library journal, 2020,7,5,1-21. DOI: https://doi.org/10.4236/oalib.1106302.
24. N.Thallaj. Indian journal of advanced chemistry, 2021. 1, 2, 20-26. DOI: https://doi.org/10.54105/ijac.B2009.101221
25. N.Thallaj. Indian journal of advanced chemistry, 2022. 2, 2, 1-11. DOI: https://doi.org/10.54105/ijac.D2015.102222
26. N.Thallaj. Indian journal of advanced chemistry, 2, 1, 2022. 5-9. DOI: https://doi.org/10.54105/ijac.C2012.041322
27. N.Thallaj. Indian journal of advanced chemistry, 2, 1, 2022. 10-14. DOI: https://doi.org/10.54105/ijac.C2013.041322
28. N.Thallaj.Xi'an ShiyouDaxueXuebao (ZiranKexue Ban)/ Journal of Xi'an Shiyou University, Natural Sciences Edition.2022.65, 06. 289-301. DOI: https://doi.org/10.17605/OSF.IO/W8RS5
29. N.Thallaj.Xi'an ShiyouDaxueXuebao (ZiranKexue Ban)/ Journal of Xi'an Shiyou University, Natural Sciences Edition.2022.65, 06. 313-328. DOI: https://doi.org/10.17605/OSF.IO/K8RFE
30. Z. MALEK, A. ABBOOD, N.THALLAJ. Xi'an ShiyouDaxueXuebao (ZiranKexue Ban)/ Journal of Xi'an Shiyou University, Natural Sciences Edition.2022.65, 06. 302-312. DOI: https://doi.org/10.17605/OSF.IO/K56XY
31. N.Thallaj. 2022. 65, 7, 169-184. Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/Journal of Xi'an Shiyou University, Natural Sciences Edition. DOI: https://doi.org/10.17605/OSF.IO/7F23D
32. Z. MALEK,2022. 65, 7, 143-152. Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/Journal of Xi'an Shiyou University, Natural Sciences Edition. DOI: https://doi.org/10.17605/OSF.IO/2UNHK
33. N.Thallaj. 2022. 65, 7, 110-142. Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/Journal of Xi'an Shiyou University, Natural Sciences Edition. DOI: https://doi.org/10.17605/OSF.IO/KZRDJ
34. N Thallaj, (2023). 44,(6),21-29. Tishreen University Journal-Medical Sciences Series.
35. N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2022. 2, 3,1-28. DOI: https://doi.org/10.54105/ijapsr.C4018.042322
36. N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2022. 2, 4,1-15. DOI: https://doi.org/10.54105/ijapsr.C4016.062422
37. N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2023. 3, 2,1-18. DOI: https://doi.org/10.54105/ijapsr.C4016.062422
38. N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2022. 2, 6,1-12. DOI: https://doi.org/10.54105/ijapsr.C4015.102622
39. N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2023. 3, 3,1-10. DOI: https://doi.org/10.54105/ijapsr.C4012.043323
40. N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024. 4, 1,32-52. DOI: https://doi.org/10.54105/ijapsr.A4036.124123
41. O. Khatib, T. Alshimale, A. Alsaadi, N. Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024. 4, 3,1-15. DOI: https://doi.org/10.54105/ijapsr.C4040.04030424
42. N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024. 4, 5,29-49. DOI: https://doi.org/10.54105/ijapsr.E4049.04050824
43. N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024.4, 4,7-21. DOI: https://doi.org/10.54105/ijapsr.D4042.04040624
44. N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024.4, 6,7-27. DOI: https://doi.org/10.54105/ijapsr.F4054.04061024
45. N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024.4, 6,33-48. DOI: https://doi.org/10.54105/ijapsr.F4055.04061024
46. Besherb S, Alallan L, Hassan Agha MA, AIshamas I, Thallaj N. Influence of soil salinity on the chemical composition of essential oil of Rosmarinus Officinalis in Syria, Research J. Pharm. and Tech. 2024; 17(5). DOI: https://doi.org/10.52711/0974-360X.2024.00358
47. Isbera M, Abbood A, Ibrahim W. Weight and Content Uniformity of Warfarin Sodium Half Tablets. Research J. Pharm. and Tech. 2016; 9(3):215-218. DOI: https://doi.org/10.5958/0974-360X.2016.00039.1
48. Abbood A, Layka R. Weight and content uniformity Study of captopril half-tablets. Research J. Pharm. and Tech. 2017;10(6):1621-1626. DOI: https://doi.org/10.5958/0974-360X.2016.00039.1.
49. Mahfouz H, Assaf A, Abbood A. Survey of Usage and Awareness of Ibuprofen Among the Syrian Population. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), Volume-4 Issue-5, August 2024, pages 23-28. DOI: https://doi.org/10.54105/ijapsr.E4048.04050824.
50. Abbood A. Overview of Analytical Methods for Characterizing the Charge Heterogeneity of Antibody-Drug Conjugates. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), Volume-4 Issue-5, August 2024, pages 16-22. DOI: https://doi.org/10.54105/ijapsr.E4047.04050824.
51. Nouira R, Abbood A. Assessment of Knowledge About High Blood Pressure Among Syrians. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), Volume-4 Issue-6, October 2024, pages 28-32. DOI: https://doi.org/10.54105/ijapsr.F4053.04061024.
52. Al-Saroukhy R, Al-Kara R, Habib R, Abbood A. Assessment of use and Awareness of Diclofenac in Syria. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), Volume-4 Issue-6, October 2024, pages 1-6. DOI: https://doi.org/10.54105/ijapsr.F4052.04061024.
53. Besher S, Alallan L, Hasan Agha MI, Alshamaa I, Thallaj N. Influence of Soil Salinity on the Chemical Composition of Essential Oil of Rosmarinus officinalis in Syria. Research Journal of Pharmacy and Technology. 2024; 17(5):2282-8. DOI: https://doi.org/10.52711/0974-360X.2024.00358.
54. Khatib O, Alshimale T, Alsaadi A, Thallaj N. The Global Impact of HIV: A Comprehensive Review. IJAPSR, vol. 4, no. 3, pp. 6–19, Apr. 2024. DOI: https://doi.org/2010.54105/ijapsr.C4040.04030424.
55. Salloum R, Baddour F, Abbood A. A Questionnaire to Evaluate Undergraduate Students' Consumption and Awareness of Non-Steroidal Anti-Inflammatory Drugs in Syria. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), Volume-4 Issue-4, June 2024, pages 1-6. DOI: https://doi.org/10.54105/ijapsr.C4041.04040624.
56. Zanboua R, Abbood A. Survey of Knowledge About the Interaction Between Food and Drugs Among the Syrian Population. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), Volume-4 Issue-4, June 2024, pages 22-28. DOI: https://doi.org/10.54105/ijapsr.D4044.04040624.
57. Qattan M, Dashash M, S Malek Z. Enhancing Academic Success: A mixed Study on the Influencing Factors among Pharmacy Students in Syrian Universities. F1000Res. 2024 Oct 11;13:868. PMID: 39483707; PMCID: PMC11525093. DOI: https://doi.org/10.12688/f1000research.151218.2
58. Thallaj, N. (2022). Design and Synthesis Ligands Tetradents Substituted with Halogenes in α- Position and Conjugation with Riboflavin (Bioconjugates): Conjugate ligands Type TPA's with Flavonoids as un Electron Mediator. Biomedicine and Chemical Sciences, 1(2), 47–56. DOI: https://doi.org/10.48112/bcs.v1i2.85

AUTHOR PROFILE

Juan Farhad Alrasho, A Student at The College of Pharmacy. Worked As A Pharmacist For Two Years During My University Studies. Looking Forward to Finding A Job That Will Develop And Increase My Pharmaceutical skills and raise My academic level. rain and work as a community pharmacist. With an integrated team of pharmacists to provide medical advice, give advice to patients, and dispense medication and appropriate treatment.

HIGHLIGHTS:
A broad-based experience in synthesis and characterization of organic and organo-metallic compounds. Multiple-step organic and organometallic synthesis. Carbohydrate Chemistry, Microwave synthesis, Solid phase synthesis, Enantioselective synthesis, Homogenous catalysis, Synthetic techniques including working on a Schlenck line, through a glovebox and in a clean rooms. Crystallogenesis experience especially in growing single crystals under inert conditions. Characterization of organic products and organometallic complexes by a variety of NMR techniques (1H, 13C, 31P, 15N, 19F) 1D and 2D, 1HNMR, FT-IR spectroscopy, UV-Visible-NIR spectroscopy, variable temperatures, Mass spectrometry, electrochemistry (conductimetry, cyclic voltammetry), chromatography techniques, including column, TLC preparative, GC, GC mass and HPLC chromatography. Damascus, Syria.

Farhad Khalil Sofi, student at the Faculty of Pharmacy looking for a job in the scientific representative for pharmaceutical companies, where apply my knowledge and skills for continuous improvement. I am looking forward for my first work experience. Part of the activites of the first scientific day of the faculty of Pharmacy at dama rose hotel lect
entitled:
1. Local Pharamceutical Industries betweer and ambition.
2. Pharmacological genetic applications in improving health care.
3. Pharmacological curves.
4. New Horizons in cancer Sciences.
5. Smoking and Anesthesia.

HIGHLIGHTS:
A broad-based experience in synthesis and characterization of organic and organo-metallic compounds. Multiple-step organic and organometallic synthesis. Carbohydrate Chemistry, Microwave synthesis, Solid phase synthesis, Enantioselective synthesis, Homogenous catalysis, Synthetic techniques including working on a Schlenck line, through a glovebox and in a clean rooms. Crystallogenesis experience especially in growing single crystals under inert conditions. Characterization of organic products and organometallic complexes by a variety of NMR techniques (1H, 13C, 31P, 15N, 19F) 1D and 2D, 1HNMR, FT-IR spectroscopy, UV-Visible-NIR spectroscopy, variable temperatures, Mass spectrometry, electrochemistry (conductimetry, cyclic voltammetry), chromatography techniques, including column, TLC preparative, GC, GC mass and HPLC chromatography.
Syria, Damascus.

Dr. Nasser Thallaj, PhD in Chemical Sciences *professor* Member of American Chemical Society (ACS) 2020- presente time: professor in the biomedical Science program.2020- Present time: *Assistant professor* position. Faculty of pharma *alrashed university,* Damascus , syria
From 15 june 2019 – 31 July 2020: President Of *AlJazeera University*, Damascus, Syria.
From Abril 1st 2019 – 15jun: vice president for scientific affairs and Dean of Faculty of pharmacy AlJazeera University, Damascus, Syria.
From October 1st 2018-15 march 2020: Dean of Faculty of pharmacy *AlJazeera University,* Damascus, Syria.
2017-31 July2020: *Assistant professor* position. Faculty of pharmacy, *AlJazeera University,* Damascus, Syria
- 2015-2017: *Assistant professor* position.
Faculty of pharmacy, *Syrian Private University,* Damascus, Syria
- 2015- 2016: Consultant in Ugarit Education Group: foundation of *AlManara University.*
- 2014-2015: vice president for scientific affairs (in charge), *University of Kalamoon,* Dier Attieh, Syria.
- 2014-2015: In charge of higher education affairs, *University of Kalamoon*, Dier Attieh, Syria.
- 2012-2014: Dean of Faculty of applied Sciences, *University of Kalamoon*. Dier Attieh, Syria.
- 2010-2013: Head of Department of Chemistry. Faculty of applied Sciences, *University of Kalamoon*. Dier Attieh, Syria
-2008: *Assistant professor* position. Faculty of applied Sciences, *University of Kalamoon.* Dier Attieh, Syria
2007-2008 : Post-Doctoral position. *Laboratory of NanoOrganic Chemistry, and Supramolecular Materials,* thesis title : *drug delivery system Department* of Chemistry. *University Notre Dame de la Paix*. Namur, Belgium.